5,638 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Bridgewater Advisors Inc.

Bridgewater Advisors Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,638 shares of the biopharmaceutical company's stock, valued at approximately $588,000.

A number of other institutional investors have also made changes to their positions in GILD. Tectonic Advisors LLC boosted its stake in Gilead Sciences by 0.6% during the 1st quarter. Tectonic Advisors LLC now owns 81,785 shares of the biopharmaceutical company's stock worth $9,164,000 after acquiring an additional 499 shares during the last quarter. Larson Financial Group LLC raised its holdings in Gilead Sciences by 24.7% in the first quarter. Larson Financial Group LLC now owns 11,476 shares of the biopharmaceutical company's stock worth $1,286,000 after purchasing an additional 2,271 shares during the period. Sage Mountain Advisors LLC boosted its position in shares of Gilead Sciences by 10.2% during the first quarter. Sage Mountain Advisors LLC now owns 6,735 shares of the biopharmaceutical company's stock worth $755,000 after purchasing an additional 623 shares in the last quarter. Wealthfront Advisers LLC grew its holdings in shares of Gilead Sciences by 28.4% in the 1st quarter. Wealthfront Advisers LLC now owns 213,912 shares of the biopharmaceutical company's stock valued at $23,969,000 after buying an additional 47,269 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences by 24.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company's stock valued at $10,565,000 after buying an additional 18,368 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the subject of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Morgan Stanley lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Stock Performance

Shares of GILD traded down $1.00 during midday trading on Thursday, reaching $108.85. The stock had a trading volume of 2,518,299 shares, compared to its average volume of 7,662,808. The firm has a market cap of $135.40 billion, a PE ratio of 22.90, a P/E/G ratio of 0.71 and a beta of 0.29. The firm has a 50 day simple moving average of $108.37 and a 200-day simple moving average of $104.94. Gilead Sciences, Inc. has a one year low of $70.78 and a one year high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,000 shares of company stock worth $7,844,775. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.